Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine PK and Safety in Pediatric OAB
NCT00857896Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2009
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fesoterodine in overactive bladder (OAB), neurogenic detrusor overactivity (NDO), sponsored by Pfizer. Started Mar 2009; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT00857896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00857896.